Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (111-120 of 237) with videos related to

Pageof 24
Sort By:
Oncotarget|January 18, 2021
Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancerKrastan B Blagoev, Roumen Iordanov, Mengxi Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cellsMerrill E Goldsmith, Masaki Kitazono, Patrick Fok, et al.
Cancer|January 28, 2003
Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastasesBradford J Wood, Jame Abraham, Julia L Hvizda, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 3, 2012
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studiesLaleh Amiri-Kordestani, Agnes Basseville, Karen Kurdziel, et al.
Critical Reviews in Oncology/Hematology|December 21, 2004
Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizationsTito Fojo, Nick Farrell, Waldo Ortuzar, et al.
Seminars in Oncology|October 24, 2018
Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 yearsPaul E Sackstein, Daniel S O'Neil, Alfred I Neugut, et al.
Novartis Foundation Symposium|May 7, 2002
Reversal of multidrug resistance: lessons from clinical oncologySusan F Bates, Clara Chen, Robert Robey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumorsBrigitte C Widemann, Wendy Goodspeed, Anne Goodwin, et al.
Cancer|March 20, 2002
Percutaneous tumor ablation with radiofrequencyBradford J Wood, Jeffrey R Ramkaransingh, Tito Fojo, et al.
The Oncologist|January 4, 2021
Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine TumorsClarisse Dromain, Arturo Loaiza-Bonilla, Beloo Mirakhur, et al.
Pageof 24

Showing results (111-120 of 237) with videos related to

Sort By:
Pageof 24
Oncotarget|January 18, 2021
Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancerKrastan B Blagoev, Roumen Iordanov, Mengxi Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cellsMerrill E Goldsmith, Masaki Kitazono, Patrick Fok, et al.
Cancer|January 28, 2003
Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastasesBradford J Wood, Jame Abraham, Julia L Hvizda, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 3, 2012
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studiesLaleh Amiri-Kordestani, Agnes Basseville, Karen Kurdziel, et al.
Critical Reviews in Oncology/Hematology|December 21, 2004
Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizationsTito Fojo, Nick Farrell, Waldo Ortuzar, et al.
Seminars in Oncology|October 24, 2018
Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 yearsPaul E Sackstein, Daniel S O'Neil, Alfred I Neugut, et al.
Novartis Foundation Symposium|May 7, 2002
Reversal of multidrug resistance: lessons from clinical oncologySusan F Bates, Clara Chen, Robert Robey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumorsBrigitte C Widemann, Wendy Goodspeed, Anne Goodwin, et al.
Cancer|March 20, 2002
Percutaneous tumor ablation with radiofrequencyBradford J Wood, Jeffrey R Ramkaransingh, Tito Fojo, et al.
The Oncologist|January 4, 2021
Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine TumorsClarisse Dromain, Arturo Loaiza-Bonilla, Beloo Mirakhur, et al.
Pageof 24